[Source: PRNewswire-USNewswire] – The Side-Out Foundation and
its Dig Pink(R) Volleyball Breast Cancer Awareness Campaign will launch a
first of its kind clinical trial this month to examine the effects of
individualized treatment on patients with metastatic breast cancer.
Individualized treatment, known as targeted therapy, provides doctors a better
way to tailor cancer treatment and offers the hope of more precisely targeting
the cancerous cells, which would reduce side effects and improve quality of
life.
The trial protocol will bring together the diverse skills and unique
experience of community oncologists, nurses and researchers in the field
molecular medicine. Clinical trials will occur at TGen Clinical Research
Services (TCRS) at Scottsdale Healthcare and Fairfax Northern Virginia
Hematology – Oncology. TGen Drug Development Services (TD2) will manage the
trial for the Side-Out Foundation. The two major contributing laboratories are
Caris Diagnostics, and George Mason University’s Center for Applied Proteomics
and Molecular Medicine.
For more information: Side-Out Foundation Teams With Leading Laboratories and Medical Professionals to Battle Breast Cancer With Personalized Therapy